Abstract. The four serotypes of mosquito-borne dengue virus (DENV-1, -2, -3, and -4) that circulate in humans each emerged from an enzootic, sylvatic cycle in non-human primates. Herein, we present the first study of sylvatic DENV infection dynamics in a primate. Three African green monkeys were inoculated with 10 5 plaque-forming units (pfu) DENV-2 strain PM33974 from the sylvatic cycle, and one African green monkey was inoculated with 10 5 pfu DENV-2 strain New Guinea C from the human cycle. All four monkeys seroconverted (more than fourfold rise in 80% plaque reduction neutralization titer [PRNT 80 ]) against the strain of DENV with which they were inoculated; only one (33%) of three monkeys infected with sylvatic DENV showed a neutralizing antibody response against human-endemic DENV. Virus was detected in two of three monkeys inoculated with sylvatic DENV at low titer ( 1.3 log 10 pfu/mL) and brief duration ( 2 days). Clinical signs included rash and elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels.
Mosquito-borne dengue virus (DENV; genus Flavivirus) is one of only two arthropod-borne viruses to have established a transmission cycle endemic to humans that is ecologically and evolutionarily distinct from its enzootic ancestors. 1 In its human transmission cycle, the virus comprises four antigenically and genetically distinct serotypes (DENV-1, -2, -3, and -4); infection with one serotype conveys lifelong protection against homologous challenge but only transient protection against heterologous infection with another serotype. 2, 3 Although most infections are subclinical, a fraction results in classical dengue fever (DF), a self-limited febrile illness, and some of these patients progress to severe dengue disease. 4 The lack of an animal model that recapitulates human dengue disease has been a major barrier to the development of DENV vaccines and therapeutics. Replication of human-endemic DENV in non-human primates (NHPs) 5 is muted in intensity and duration relative to replication in humans, 6 and infection with human-endemic DENV produces disease in NHPs only when administered at doses that greatly exceed those delivered by the mosquito. 1 Each of four human-endemic DENV serotypes emerged from enzootic ancestors maintained in a sylvatic cycle between NHPs and canopy-dwelling Aedes mosquitoes. 1, 7 These sylvatic cycles remain active in the forests of southeast Asia and west Africa. Spillover of sylvatic DENV into humans, sometimes causing severe disease, has been repeatedly documented. [8] [9] [10] [11] [12] [13] [14] [15] Thus, continued circulation of sylvatic DENV may threaten future control of human DENV when a DENV vaccine becomes available. 7 Because the replication and immunogenicity of sylvatic DENV in its NHP hosts have not previously been investigated, some mathematical models of sylvatic DENV population dynamics and spillover risk have used infection parameters derived from studies of humanendemic DENV in NHPs. 16 However, infection dynamics of arboviruses in reservoir and non-reservoir hosts can differ substantially. 17, 18 Yellow fever virus (YFV) offers a particularly dramatic example of this difference: YFV infection rarely causes overt illness in African NHPs that serve as reservoir hosts of its ancestral sylvatic cycle, whereas YFV infection of New World monkeys results in high rates of disease and death (reviewed in ref. 1). Mandl and others 19 showed that the YFV-17D live-attenuated vaccine strain replicated to lower levels and for shorter duration in YFV reservoir (sooty mangabeys [Cercocebus atys]) than novel (rhesus macaques [Macaca mulatta]) hosts. Moreover, neutralizing antibody responses to YFV-17D were significantly lower in sooty mangabeys than in rhesus macaques 28 days post-infection (pi); neutralizing antibodies waned to undetectable levels by 120 days pi in sooty mangabeys but were maintained at high levels in rhesus macaques. If replication of sylvatic and human-endemic DENV in NHPs differs to a similar degree, models of sylvatic DENV transmission dynamics that rely on infection dynamics of human-endemic DENV in NHPs may be misleading.
In this study, we infected African green monkeys (AGMs; Chlorocebus sabaeus), a known host of sylvatic DENV-2 in West Africa, 1 with a West African sylvatic strain of DENV-2. AGMs were provided by Primate Products (Miami, FL) from a colony maintained in St. Kitts. Sixteen adults were first screened by plaque reduction neutralization titer (PRNT) essentially as previously described 20, 21 to ensure that they had not been exposed to DENV-1, -2, -3, or -4, YFV, or West Nile virus. All 16 NHPs were seronegative (PRNT 80 20) for all viruses. Four males weighing 6 kg were then quarantined in the Tulane National Primate Research Center (TNPRC) in Covington, Louisiana. All procedures using these animals were performed by the clinical veterinary staff at the TNPRC under the guidance of veterinarians, and they were approved by the Institutional Animal Care and Use Committee (IACUC) of Tulane University in compliance with the American Association for Laboratory Animal Science (AALAS) "Policy on the Human Care and Use of Laboratory Animals." Monkeys were anesthetized with ketamine at an intramuscular (i.m.) dose of 10 mg/kg body weight on day 0 of the study; and other flaviviruses 19 in NHPs and DENV vaccine candidates in humans. 23 Inocula were administered in a total volume of 1 mL, with 0.5 mL administered to each upper arm.
Sylvatic DENV-2 strain PM33974 was isolated from a pool of Ae. africanus mosquitoes in Guinea in 1981 by inoculation into Toxorhynchites amboinensis mosquitoes and subsequently passaged five times in Ae. albopictus C6/36 cells to create the stock used for infections. This strain has been studied extensively in cell culture and mouse models of human infection.
24,25 DENV-2 NGC was derived from the prototype strain (isolated in 1944) without passage in mouse brains. 26 DENV-2 NGC was chosen as a control, because in a previous experiment, this strain produced viremia in 100% of rhesus macaques (M. mulatta) injected with 10 5 pfu. 22 The complete genome sequence of the DENV-2 PM33974 lineage used in this study has been determined (Genbank accession no. EF105378.1), 24 but only the structural genes (capsid, premembrane, and envelope genes; 807 amino acids in total) of the DENV-2 NGC lineage used in this study have been sequenced (AY243468.1). 22 The structural genes of the two strains showed 93% amino acid identity. To compare whole genomes, the sequence of a different strain of DENV-2 NGC (AF038403) was aligned to the complete genome of DENV-2 PM33974. The two sequences showed 82% nucleotide identity across the entire genome, 94% amino acid identity in the coding region, and 92% nucleotide identity at both the 5 and 3 untranslated regions. To compare the replication of the two viruses in cell culture, plaque size of each virus was measured in C6/36 cells (9 plaques/virus) and AGM kidney Vero cells (30 plaques/virus) as previously described. 27 DENV-2 NGC produced substantially smaller plaques than DENV-2 PM33974 in C6/36 cells (mean in millimeters ± 1 SE = 0.29 ± 0.001 versus 0.40 ± 0.001; Student's t test, degree of freedom [df] = 16, P 0.0001) but slightly larger plaques than DENV-2 PM33974 in Vero cells (0.19 ± 0.002 versus 0.15 ± 0.012; Student's t test, df = 58, P = 0.045).
Serum was collected on days 1-10, 12, 14, 16, and 18 pi to monitor viremia and days −3 and 28 pi to assay neutralizing antibodies by PRNT 80 against DENV-2 strains NGC and PM33974. Blood was drawn to conduct a complete blood count and measure components of serum biochemistry (bilirubin, alkaline phosphatase, creatinine, creatinine phosphokinase, glucose, aspartate aminotransferase [AST], alanine aminotransferase [ALT], blood urea nitrogen [BUN] , and albumin/ globulin ratio) and electrolytes (Na, Cl, and K) on study days −3, 4, 7, and 28 pi. Rectal temperature, behavior, vital signs, weight, and skin condition were monitored on days −3, 0-10, 12, 14, 16, 18, and 28 pi. Viremia was quantified by serial dilution of serum and immunostaining in Vero cells as previously described 20, 21 ; virus titers are shown in Table 1 . To enhance sensitivity, sera were also passaged one time in 1 well of a 24-well plate of confluent Vero cells, and resulting viral progeny in cell culture supernatants was detected by serial dilution and immunostaining. Detection of virus post-passage is indicated in Table 1 ( †).
All four monkeys seroconverted (more than fourfold rise in PRNT 80 ) with high PRNT 80 titers against the strain of DENV with which they were inoculated ( Table 2) , showing that all four had been infected. The monkey infected with DENV-2 NGC showed a substantial neutralizing antibody response to sylvatic DENV-2 PM33974. These data are consistent with our previous finding that sera from 19 vaccinees who had received a live-attenuated DENV-2 vaccine as well as sera from two convalescent DENV-2 patients all effectively neutralized (PRNT 80 20) four different strains of humanendemic DENV-2 and four strains of sylvatic DENV-2 that originated in both Asia and West Africa. 28 However, of the three monkeys infected with sylvatic DENV-2, only one (33%) monkey seroconverted to DENV-2 NGC. Blaney and others 29 have also reported variation in neutralization of different strains of DENV within a serotype. Blaney and others 29 tested the neutralizing activity of serum from vaccinees who received a live-attenuated tetravalent dengue vaccine against five different DENV strains per serotype, including each of the four strains incorporated into the vaccine. The study found, for each serotype, that (1) the vaccine (infecting) strain was robustly neutralized, (2) at least one strain was more efficiently neutralized than the vaccine strain, and (3) although all strains of DENV-1, -2, and -4 were efficiently neutralized, two of five DENV-3 strains were not. 29 The study by Blaney and others 29 and other studies 30, 31 have raised concerns that there could be gaps in vaccine protection caused by strain variation. Similarly, the asymmetry in neutralization of DENV-2 NGC by monkeys infected with DENV-2 PM33971 suggests that NHP populations could be susceptible to some strains of human DENV, even if previously exposed to the homologous serotype of sylvatic DENV. DENV has been shown to spill back from humans into NHPs, 32 and such spillback could result in the formation of new sylvatic cycles. 1 Viremia was detected in two of three monkeys infected with DENV-2 PM33974 after an average of 3.5 days, it persisted for an average of 1.5 days, and it reached a maximum titer of 1.3 log 10 pfu/mL in the monkey in which viremia could be detected without amplification (Table 1 ). In contrast, in the monkey infected with human-endemic DENV-2 NGC, viremia was detectable after 4 days, it persisted for 4 days, and it reached a maximum titer of 2.0 log 10 pfu/mL. Althouse and others 5 have recently conducted a meta-analysis of the effects of serotype and host species, among other factors, on time to viremia and duration of viremia during human-endemic DENV replication in NHPs. This analysis included four studies of AGMs. Althouse and others 5 detected a significant effect of serotype but not NHP species on these variables; for DENV-2, the median time to viremia was approximately 2.63 days, and the median duration of viremia was 5.13 days. Additionally, Halstead and others 33 infected AGMs with 1 + 10 5 pfu DENV-2 strain 16681 and reported a maximum viremia titer of 2.0 log 10 pfu. Thus, the values reported in this study for DENV-2 NGC are consistent with previous studies of human-endemic DENV-2 in AGMs and other NHPs. However, contrary to our initial hypothesis, in AGMs, the magnitude of sylvatic DENV-2 PM33974 viremia was similar to that of human-endemic DENV-2, and the duration of detectable viremia was lower than that of human-endemic DENV-2.
All monkeys exhibited a rash that occurred after viremia had dropped to undetectable levels (Table 1) ; this rash was characterized as primarily erythema, with some areas of papulas. All four monkeys experienced increases in ALT and AST levels p.i. (Figure 1) ; we did not attempt statistical analysis of this small sample. In one monkey (JT10), hematocrit showed a dramatic decrease on day 28 concurrent with a sharp increase in BUN (Figure 2 ), findings consistent with gastrointestinal bleeding, a sign of dengue disease. Confirmation of such bleeding would require detection of occult blood in stool; unfortunately, stool was not examined in this experiment. There were no other consistent or dramatic changes in any of the other parameters measured between the preinfection and p.i. periods, and our values were generally in line with previously reported values for free-living St. Kitts AGMs brought into captivity. 34 Monkeys exhibited no increase in body temperature ( Figure 3 ) and no change in body condition beyond what was expected for animals being anesthetized daily. There were no dramatic differences between replication of or response to human and sylvatic DENV-2 in any values measured.
A National Institute of Allergy and Infectious Diseases (NIAID) workshop convened in 2010 to consider fruitful directions for development of animal models of dengue disease urged researchers to investigate infection dynamics of sylvatic 36 DENV in NHPs. 35 Their rationale was that these enzootic viruses may show patterns of replication and pathogenicity in reservoir hosts that more closely reflect those of humanendemic DENV in humans than human-endemic DENVs in NHPs. Contrary to this expectation, our findings, albeit limited by a small sample size, show that levels of sylvatic DENV-2 virus replication in AGMs were substantially lower than those of human-endemic DENV in hospitalized or ambulatory cases of human dengue disease. 6 Furthermore, primary infection by sylvatic DENV-2 of AGMs in this study recapitulated infection dynamics and clinical signs, including elevated ALT and rash, observed in humans administered 10 5 pfu live-attenuated DENV-4 vaccine. 23 However, our finding that one monkey exhibited increased BUN coupled with decreased hematocrit is intriguing and warrants additional study. The duration of sylvatic DENV-2 replication in AGMs that we measured was lower than that of human-endemic DENV-2 replication in NHPs. 5 Thorough documentation of such differences will be important for refining models of sylvatic DENV population dynamics. Thus, the results of this study provide the impetus to conduct larger studies involving additional sylvatic and human-endemic DENV strains and greater host sample sizes to fully characterize the infection dynamics of sylvatic DENV in reservoir hosts.
